Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Esophageal Neoplasms | 36 | 2024 | 372 | 5.700 |
Why?
|
Barrett Esophagus | 29 | 2024 | 340 | 4.700 |
Why?
|
Esophagoscopy | 24 | 2024 | 156 | 4.340 |
Why?
|
Optical Imaging | 10 | 2020 | 65 | 3.350 |
Why?
|
Precancerous Conditions | 12 | 2020 | 282 | 2.850 |
Why?
|
Adenocarcinoma | 21 | 2022 | 1023 | 2.140 |
Why?
|
Esophagus | 12 | 2020 | 216 | 2.070 |
Why?
|
Colonoscopy | 8 | 2018 | 236 | 1.990 |
Why?
|
Microscopy | 10 | 2024 | 116 | 1.780 |
Why?
|
Colorectal Neoplasms | 9 | 2019 | 574 | 1.760 |
Why?
|
Endoscopy, Gastrointestinal | 8 | 2020 | 241 | 1.680 |
Why?
|
Endoscopy | 8 | 2024 | 280 | 1.600 |
Why?
|
Early Detection of Cancer | 10 | 2024 | 361 | 1.450 |
Why?
|
Colonic Neoplasms | 3 | 2019 | 248 | 1.190 |
Why?
|
Image Enhancement | 9 | 2015 | 163 | 1.130 |
Why?
|
Colonic Polyps | 4 | 2018 | 78 | 1.060 |
Why?
|
Gastrointestinal Neoplasms | 4 | 2020 | 79 | 0.940 |
Why?
|
Adenoma | 3 | 2015 | 129 | 0.910 |
Why?
|
Microscopy, Confocal | 12 | 2019 | 348 | 0.900 |
Why?
|
Gastroenterology | 4 | 2021 | 196 | 0.820 |
Why?
|
Internationality | 2 | 2021 | 131 | 0.820 |
Why?
|
Carcinoma, Squamous Cell | 6 | 2024 | 670 | 0.820 |
Why?
|
Physicians, Women | 2 | 2021 | 47 | 0.770 |
Why?
|
Developing Countries | 1 | 2024 | 270 | 0.760 |
Why?
|
Sensitivity and Specificity | 15 | 2020 | 2051 | 0.760 |
Why?
|
Biopsy | 9 | 2024 | 1236 | 0.750 |
Why?
|
Microscopy, Fluorescence | 4 | 2015 | 325 | 0.710 |
Why?
|
Image Interpretation, Computer-Assisted | 5 | 2018 | 217 | 0.670 |
Why?
|
Orthomyxoviridae | 1 | 2019 | 50 | 0.620 |
Why?
|
Laboratories | 1 | 2019 | 82 | 0.600 |
Why?
|
Neoplasms | 3 | 2024 | 2792 | 0.600 |
Why?
|
Molecular Imaging | 3 | 2013 | 61 | 0.590 |
Why?
|
Physician's Role | 2 | 2021 | 166 | 0.580 |
Why?
|
Humans | 78 | 2024 | 124906 | 0.570 |
Why?
|
Carcinoma in Situ | 1 | 2018 | 71 | 0.570 |
Why?
|
Intestinal Polyps | 2 | 2015 | 29 | 0.550 |
Why?
|
Gastroesophageal Reflux | 3 | 2009 | 295 | 0.520 |
Why?
|
Laser Therapy | 2 | 2009 | 249 | 0.510 |
Why?
|
Neoplasms, Squamous Cell | 1 | 2015 | 8 | 0.490 |
Why?
|
Gastroscopy | 2 | 2013 | 100 | 0.480 |
Why?
|
Endoscopes | 4 | 2019 | 20 | 0.480 |
Why?
|
Mucous Membrane | 3 | 2012 | 90 | 0.470 |
Why?
|
Societies, Medical | 1 | 2018 | 695 | 0.460 |
Why?
|
China | 5 | 2024 | 245 | 0.450 |
Why?
|
Proctoscopy | 1 | 2013 | 6 | 0.440 |
Why?
|
Population Surveillance | 1 | 2016 | 388 | 0.440 |
Why?
|
Adenomatous Polyps | 1 | 2013 | 13 | 0.420 |
Why?
|
Anus Neoplasms | 2 | 2023 | 38 | 0.420 |
Why?
|
Influenza, Human | 1 | 2019 | 658 | 0.400 |
Why?
|
Rectal Neoplasms | 1 | 2013 | 79 | 0.400 |
Why?
|
Cell Transformation, Neoplastic | 2 | 2015 | 618 | 0.400 |
Why?
|
Health Care Costs | 1 | 2015 | 371 | 0.390 |
Why?
|
Cryosurgery | 1 | 2012 | 47 | 0.380 |
Why?
|
Endosonography | 3 | 2019 | 79 | 0.370 |
Why?
|
Gastroenterologists | 2 | 2021 | 11 | 0.370 |
Why?
|
Stomach | 1 | 2013 | 269 | 0.350 |
Why?
|
Colitis, Ulcerative | 2 | 2012 | 205 | 0.340 |
Why?
|
Lasers, Gas | 1 | 2009 | 7 | 0.320 |
Why?
|
Middle Aged | 21 | 2024 | 26879 | 0.310 |
Why?
|
Myocarditis | 2 | 2002 | 130 | 0.310 |
Why?
|
Digestive System Surgical Procedures | 2 | 2008 | 85 | 0.310 |
Why?
|
Iodides | 3 | 2024 | 15 | 0.300 |
Why?
|
Endoscopic Mucosal Resection | 2 | 2022 | 68 | 0.300 |
Why?
|
Fluorescent Dyes | 5 | 2013 | 261 | 0.300 |
Why?
|
Fiber Optic Technology | 5 | 2024 | 46 | 0.290 |
Why?
|
Autoimmune Diseases | 2 | 2002 | 251 | 0.290 |
Why?
|
Tomography, Optical Coherence | 6 | 2013 | 516 | 0.280 |
Why?
|
Catheter Ablation | 2 | 2022 | 236 | 0.270 |
Why?
|
Esophageal pH Monitoring | 1 | 2006 | 3 | 0.270 |
Why?
|
Hernia, Hiatal | 1 | 2007 | 55 | 0.270 |
Why?
|
Image Processing, Computer-Assisted | 4 | 2024 | 580 | 0.260 |
Why?
|
Aged, 80 and over | 8 | 2015 | 6588 | 0.260 |
Why?
|
Electric Impedance | 1 | 2006 | 58 | 0.260 |
Why?
|
HIV Infections | 3 | 2023 | 1894 | 0.250 |
Why?
|
Coloring Agents | 3 | 2024 | 80 | 0.250 |
Why?
|
Female | 27 | 2024 | 66678 | 0.250 |
Why?
|
Male | 25 | 2024 | 61395 | 0.240 |
Why?
|
Aged | 13 | 2024 | 19835 | 0.230 |
Why?
|
Deglutition Disorders | 1 | 2006 | 132 | 0.230 |
Why?
|
Methylene Blue | 1 | 2024 | 13 | 0.230 |
Why?
|
Observer Variation | 3 | 2013 | 297 | 0.220 |
Why?
|
Neoplasm Staging | 5 | 2019 | 1278 | 0.220 |
Why?
|
Predictive Value of Tests | 4 | 2024 | 2154 | 0.210 |
Why?
|
Equipment Design | 5 | 2024 | 596 | 0.210 |
Why?
|
Diagnosis, Differential | 3 | 2015 | 1885 | 0.210 |
Why?
|
Body Mass Index | 1 | 2009 | 1563 | 0.200 |
Why?
|
Career Choice | 2 | 2021 | 146 | 0.200 |
Why?
|
Carcinoma, Non-Small-Cell Lung | 1 | 2006 | 352 | 0.200 |
Why?
|
Diagnostic Imaging | 3 | 2023 | 277 | 0.200 |
Why?
|
Social Determinants of Health | 1 | 2023 | 124 | 0.190 |
Why?
|
Women, Working | 1 | 2021 | 9 | 0.190 |
Why?
|
Metaplasia | 6 | 2022 | 213 | 0.180 |
Why?
|
Algorithms | 5 | 2018 | 1624 | 0.180 |
Why?
|
Colonoscopes | 2 | 2013 | 10 | 0.180 |
Why?
|
Prospective Studies | 6 | 2015 | 6155 | 0.180 |
Why?
|
Stomach Neoplasms | 2 | 2019 | 545 | 0.180 |
Why?
|
Job Satisfaction | 1 | 2021 | 79 | 0.170 |
Why?
|
Cardiomyopathy, Dilated | 1 | 2002 | 212 | 0.170 |
Why?
|
Pancreas | 2 | 2012 | 218 | 0.170 |
Why?
|
Software | 2 | 2024 | 683 | 0.160 |
Why?
|
Kenya | 1 | 2019 | 52 | 0.160 |
Why?
|
Virus Diseases | 1 | 2002 | 280 | 0.160 |
Why?
|
Intravital Microscopy | 2 | 2016 | 16 | 0.160 |
Why?
|
United States | 6 | 2024 | 10909 | 0.160 |
Why?
|
Carbon Dioxide | 2 | 2012 | 277 | 0.160 |
Why?
|
Robotics | 2 | 2024 | 108 | 0.160 |
Why?
|
Global Health | 1 | 2024 | 561 | 0.160 |
Why?
|
Pilot Projects | 4 | 2016 | 1397 | 0.160 |
Why?
|
Mass Screening | 3 | 2019 | 783 | 0.150 |
Why?
|
Costs and Cost Analysis | 1 | 2019 | 164 | 0.150 |
Why?
|
Virtual Reality | 1 | 2018 | 28 | 0.150 |
Why?
|
Prognosis | 4 | 2015 | 4631 | 0.150 |
Why?
|
Preceptorship | 1 | 2018 | 32 | 0.150 |
Why?
|
Chemoprevention | 2 | 2016 | 58 | 0.150 |
Why?
|
Adult | 12 | 2024 | 29576 | 0.140 |
Why?
|
Health Knowledge, Attitudes, Practice | 1 | 2024 | 850 | 0.140 |
Why?
|
Feasibility Studies | 5 | 2015 | 759 | 0.140 |
Why?
|
Esophagectomy | 2 | 2016 | 64 | 0.140 |
Why?
|
Obesity | 1 | 2009 | 2237 | 0.140 |
Why?
|
Manikins | 1 | 2018 | 135 | 0.140 |
Why?
|
Swine | 3 | 2012 | 1192 | 0.140 |
Why?
|
Forecasting | 1 | 2018 | 351 | 0.140 |
Why?
|
Real-Time Polymerase Chain Reaction | 1 | 2019 | 502 | 0.140 |
Why?
|
Teaching | 1 | 2018 | 190 | 0.130 |
Why?
|
Models, Animal | 2 | 2009 | 465 | 0.130 |
Why?
|
Computers, Handheld | 1 | 2016 | 33 | 0.120 |
Why?
|
Epithelial Cells | 1 | 2020 | 909 | 0.120 |
Why?
|
Cohort Studies | 3 | 2019 | 4808 | 0.120 |
Why?
|
Proflavine | 2 | 2012 | 2 | 0.120 |
Why?
|
Capsule Endoscopes | 1 | 2015 | 1 | 0.120 |
Why?
|
Attitude of Health Personnel | 1 | 2021 | 664 | 0.120 |
Why?
|
Models, Economic | 1 | 2015 | 51 | 0.120 |
Why?
|
Colon | 2 | 2018 | 349 | 0.120 |
Why?
|
Proton Pump Inhibitors | 2 | 2009 | 258 | 0.120 |
Why?
|
Video Recording | 2 | 2013 | 182 | 0.120 |
Why?
|
Markov Chains | 1 | 2015 | 84 | 0.120 |
Why?
|
Quality-Adjusted Life Years | 1 | 2015 | 111 | 0.120 |
Why?
|
Reproducibility of Results | 4 | 2015 | 2881 | 0.110 |
Why?
|
Proctoscopes | 1 | 2013 | 2 | 0.110 |
Why?
|
Natural Orifice Endoscopic Surgery | 1 | 2015 | 64 | 0.110 |
Why?
|
Comparative Effectiveness Research | 1 | 2013 | 68 | 0.110 |
Why?
|
Contrast Media | 3 | 2011 | 473 | 0.100 |
Why?
|
Risk Factors | 4 | 2019 | 10285 | 0.100 |
Why?
|
Oropharyngeal Neoplasms | 1 | 2015 | 165 | 0.100 |
Why?
|
Hyperplasia | 1 | 2013 | 208 | 0.100 |
Why?
|
Retrospective Studies | 7 | 2022 | 16345 | 0.100 |
Why?
|
Rectum | 1 | 2013 | 100 | 0.100 |
Why?
|
Cost-Benefit Analysis | 1 | 2015 | 509 | 0.100 |
Why?
|
Endoscopic Ultrasound-Guided Fine Needle Aspiration | 1 | 2012 | 28 | 0.100 |
Why?
|
Animals | 7 | 2024 | 34057 | 0.100 |
Why?
|
Optical Fibers | 2 | 2024 | 18 | 0.100 |
Why?
|
4-Chloro-7-nitrobenzofurazan | 1 | 2011 | 3 | 0.100 |
Why?
|
Deoxyglucose | 1 | 2011 | 33 | 0.090 |
Why?
|
Intestinal Mucosa | 2 | 2013 | 776 | 0.090 |
Why?
|
Risk Assessment | 4 | 2019 | 3449 | 0.090 |
Why?
|
Gastrointestinal Tract | 1 | 2013 | 215 | 0.090 |
Why?
|
Surgical Instruments | 1 | 2010 | 56 | 0.090 |
Why?
|
Adrenergic Antagonists | 2 | 2002 | 4 | 0.090 |
Why?
|
Case-Control Studies | 2 | 2009 | 3289 | 0.090 |
Why?
|
Light | 1 | 2010 | 174 | 0.080 |
Why?
|
Calcium Channel Blockers | 2 | 2002 | 115 | 0.080 |
Why?
|
Career Mobility | 2 | 2021 | 50 | 0.080 |
Why?
|
Pattern Recognition, Automated | 1 | 2010 | 49 | 0.080 |
Why?
|
Mobile Applications | 2 | 2024 | 89 | 0.080 |
Why?
|
Needles | 1 | 2009 | 51 | 0.080 |
Why?
|
Administration, Topical | 2 | 2024 | 141 | 0.080 |
Why?
|
Pancreatic Neoplasms | 2 | 2012 | 691 | 0.080 |
Why?
|
Time Factors | 2 | 2019 | 6320 | 0.080 |
Why?
|
Biopsy, Fine-Needle | 1 | 2009 | 116 | 0.080 |
Why?
|
Loss of Heterozygosity | 1 | 2009 | 125 | 0.080 |
Why?
|
ROC Curve | 3 | 2017 | 571 | 0.080 |
Why?
|
Chromosomes, Human, Pair 1 | 1 | 2009 | 140 | 0.080 |
Why?
|
Age Factors | 1 | 2015 | 2823 | 0.080 |
Why?
|
Carcinoma, Neuroendocrine | 1 | 2008 | 34 | 0.070 |
Why?
|
Incidence | 2 | 2009 | 3140 | 0.070 |
Why?
|
Sex Distribution | 1 | 2009 | 303 | 0.070 |
Why?
|
Cross-Sectional Studies | 2 | 2024 | 3436 | 0.070 |
Why?
|
Age Distribution | 1 | 2009 | 415 | 0.070 |
Why?
|
Pregnancy Complications | 2 | 2024 | 512 | 0.070 |
Why?
|
Spectrum Analysis | 1 | 2008 | 62 | 0.070 |
Why?
|
Biopsy, Needle | 1 | 2008 | 231 | 0.070 |
Why?
|
Endoscopy, Digestive System | 1 | 2008 | 149 | 0.070 |
Why?
|
Head and Neck Neoplasms | 1 | 2012 | 502 | 0.070 |
Why?
|
Comorbidity | 2 | 2009 | 1532 | 0.070 |
Why?
|
Heartburn | 1 | 2006 | 15 | 0.070 |
Why?
|
Sex Factors | 2 | 2021 | 1287 | 0.070 |
Why?
|
Immunosuppressive Agents | 2 | 2002 | 649 | 0.060 |
Why?
|
Omeprazole | 1 | 2006 | 97 | 0.060 |
Why?
|
Hydrogen-Ion Concentration | 1 | 2006 | 432 | 0.060 |
Why?
|
Quality of Life | 1 | 2015 | 1944 | 0.060 |
Why?
|
Liver | 1 | 2012 | 1737 | 0.060 |
Why?
|
Mice | 3 | 2016 | 17583 | 0.060 |
Why?
|
Gambia | 1 | 2024 | 28 | 0.060 |
Why?
|
Immunohistochemistry | 1 | 2008 | 1691 | 0.060 |
Why?
|
Smartphone | 1 | 2024 | 37 | 0.060 |
Why?
|
Printing, Three-Dimensional | 1 | 2024 | 69 | 0.050 |
Why?
|
Enzyme Inhibitors | 1 | 2006 | 579 | 0.050 |
Why?
|
Obstetric Labor Complications | 1 | 2024 | 93 | 0.050 |
Why?
|
Surveys and Questionnaires | 2 | 2024 | 3729 | 0.050 |
Why?
|
Anal Canal | 1 | 2023 | 81 | 0.050 |
Why?
|
Single-Blind Method | 2 | 2013 | 237 | 0.050 |
Why?
|
Practice Guidelines as Topic | 1 | 2009 | 1269 | 0.050 |
Why?
|
MicroRNAs | 1 | 2009 | 835 | 0.050 |
Why?
|
Treatment Outcome | 4 | 2022 | 12405 | 0.050 |
Why?
|
Liver Neoplasms | 1 | 2012 | 1314 | 0.050 |
Why?
|
Point-of-Care Systems | 1 | 2024 | 172 | 0.050 |
Why?
|
Parental Leave | 1 | 2021 | 4 | 0.050 |
Why?
|
Cell Nucleus | 1 | 2024 | 678 | 0.050 |
Why?
|
Logistic Models | 1 | 2006 | 1812 | 0.050 |
Why?
|
Prenatal Care | 1 | 2024 | 347 | 0.050 |
Why?
|
Disease Progression | 3 | 2016 | 2060 | 0.040 |
Why?
|
Reproductive Techniques, Assisted | 1 | 2021 | 70 | 0.040 |
Why?
|
Radiation Exposure | 1 | 2021 | 42 | 0.040 |
Why?
|
Severity of Illness Index | 1 | 2009 | 2902 | 0.040 |
Why?
|
Angiotensin-Converting Enzyme Inhibitors | 1 | 2002 | 224 | 0.040 |
Why?
|
Pregnancy | 2 | 2024 | 7174 | 0.040 |
Why?
|
Occupational Exposure | 1 | 2021 | 127 | 0.040 |
Why?
|
Radiation Injuries | 1 | 2021 | 142 | 0.040 |
Why?
|
Fungal Vaccines | 1 | 1999 | 1 | 0.040 |
Why?
|
Immunoglobulin Idiotypes | 1 | 1999 | 11 | 0.040 |
Why?
|
Antibodies, Fungal | 1 | 1999 | 13 | 0.040 |
Why?
|
Cryptococcus neoformans | 1 | 1999 | 20 | 0.040 |
Why?
|
Mice, Inbred BALB C | 1 | 2002 | 1003 | 0.040 |
Why?
|
Mentors | 1 | 2021 | 148 | 0.040 |
Why?
|
Tetanus Toxoid | 1 | 1999 | 45 | 0.040 |
Why?
|
Salaries and Fringe Benefits | 1 | 2019 | 28 | 0.040 |
Why?
|
Follow-Up Studies | 2 | 2013 | 5165 | 0.040 |
Why?
|
Biomarkers, Tumor | 1 | 2007 | 1492 | 0.040 |
Why?
|
Watchful Waiting | 1 | 2019 | 70 | 0.040 |
Why?
|
CD4 Lymphocyte Count | 1 | 2019 | 231 | 0.040 |
Why?
|
Delivery of Health Care | 1 | 2024 | 607 | 0.040 |
Why?
|
Polysaccharides | 1 | 1999 | 140 | 0.040 |
Why?
|
Drug Therapy, Combination | 1 | 2002 | 1165 | 0.040 |
Why?
|
Survival Analysis | 1 | 2002 | 1507 | 0.040 |
Why?
|
Autoimmunity | 1 | 1999 | 172 | 0.040 |
Why?
|
Fellowships and Scholarships | 1 | 2021 | 281 | 0.040 |
Why?
|
Immunization, Passive | 1 | 1998 | 120 | 0.040 |
Why?
|
Regression Analysis | 1 | 2019 | 780 | 0.040 |
Why?
|
Randomized Controlled Trials as Topic | 1 | 2002 | 1116 | 0.030 |
Why?
|
Artificial Intelligence | 1 | 2020 | 241 | 0.030 |
Why?
|
Alcohol Drinking | 1 | 2019 | 343 | 0.030 |
Why?
|
Africa, Western | 1 | 2016 | 12 | 0.030 |
Why?
|
Education, Medical, Graduate | 1 | 2021 | 518 | 0.030 |
Why?
|
Education, Nursing | 1 | 2016 | 12 | 0.030 |
Why?
|
Adjuvants, Immunologic | 1 | 1998 | 383 | 0.030 |
Why?
|
Anti-Inflammatory Agents, Non-Steroidal | 1 | 1998 | 305 | 0.030 |
Why?
|
Kaplan-Meier Estimate | 2 | 2008 | 1054 | 0.030 |
Why?
|
Neck Dissection | 1 | 2015 | 18 | 0.030 |
Why?
|
Proportional Hazards Models | 1 | 2019 | 1358 | 0.030 |
Why?
|
Emergency Treatment | 1 | 2016 | 87 | 0.030 |
Why?
|
In Situ Hybridization, Fluorescence | 1 | 2017 | 762 | 0.030 |
Why?
|
Nitric Oxide | 1 | 1998 | 445 | 0.030 |
Why?
|
Equipment Failure Analysis | 1 | 2015 | 85 | 0.030 |
Why?
|
Combined Modality Therapy | 2 | 2008 | 1240 | 0.030 |
Why?
|
Mouth | 1 | 2015 | 61 | 0.030 |
Why?
|
Young Adult | 2 | 2024 | 9051 | 0.030 |
Why?
|
Waiting Lists | 1 | 2016 | 227 | 0.030 |
Why?
|
Smoking | 1 | 2019 | 1046 | 0.030 |
Why?
|
Narrow Band Imaging | 1 | 2013 | 2 | 0.030 |
Why?
|
Interferometry | 1 | 2013 | 26 | 0.030 |
Why?
|
Optical Phenomena | 1 | 2013 | 10 | 0.030 |
Why?
|
Antiviral Agents | 1 | 1998 | 750 | 0.030 |
Why?
|
Learning Curve | 1 | 2012 | 53 | 0.020 |
Why?
|
Education, Medical | 1 | 2016 | 288 | 0.020 |
Why?
|
Fluorescence | 1 | 2012 | 96 | 0.020 |
Why?
|
Disease Models, Animal | 1 | 2002 | 4353 | 0.020 |
Why?
|
Hospitals | 1 | 2014 | 388 | 0.020 |
Why?
|
Drug Evaluation, Preclinical | 1 | 2011 | 152 | 0.020 |
Why?
|
In Vitro Techniques | 1 | 2012 | 970 | 0.020 |
Why?
|
Color | 1 | 2010 | 31 | 0.020 |
Why?
|
Area Under Curve | 1 | 2011 | 318 | 0.020 |
Why?
|
Goblet Cells | 1 | 2011 | 103 | 0.020 |
Why?
|
Adolescent | 2 | 2024 | 19343 | 0.020 |
Why?
|
Staining and Labeling | 1 | 2010 | 186 | 0.020 |
Why?
|
Helicobacter pylori | 1 | 2019 | 1319 | 0.020 |
Why?
|
Calgranulin B | 1 | 2009 | 9 | 0.020 |
Why?
|
Keratin-5 | 1 | 2009 | 9 | 0.020 |
Why?
|
Cornified Envelope Proline-Rich Proteins | 1 | 2009 | 19 | 0.020 |
Why?
|
Clinical Competence | 1 | 2016 | 1000 | 0.020 |
Why?
|
Crohn Disease | 1 | 2012 | 283 | 0.020 |
Why?
|
DNA Primers | 1 | 2009 | 657 | 0.020 |
Why?
|
Radiotherapy | 1 | 2008 | 135 | 0.020 |
Why?
|
Veterans | 1 | 2019 | 1753 | 0.020 |
Why?
|
Lymph Nodes | 1 | 2009 | 383 | 0.020 |
Why?
|
Neoplasm Invasiveness | 1 | 2009 | 620 | 0.020 |
Why?
|
Cyclin D1 | 1 | 2007 | 112 | 0.020 |
Why?
|
Carcinoma | 1 | 2009 | 286 | 0.020 |
Why?
|
Early Diagnosis | 1 | 2007 | 181 | 0.020 |
Why?
|
Disease-Free Survival | 1 | 2008 | 899 | 0.020 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 1 | 2009 | 1288 | 0.020 |
Why?
|
NF-kappa B | 1 | 2007 | 455 | 0.010 |
Why?
|
RNA, Messenger | 1 | 2009 | 2815 | 0.010 |
Why?
|
Mice, Inbred C3H | 1 | 1999 | 115 | 0.010 |
Why?
|
Immunoglobulin Variable Region | 1 | 1999 | 52 | 0.010 |
Why?
|
Vaccines, Conjugate | 1 | 1999 | 78 | 0.010 |
Why?
|
Antineoplastic Agents | 1 | 2008 | 1687 | 0.010 |
Why?
|
Mice, Inbred Strains | 1 | 1999 | 308 | 0.010 |
Why?
|
DNA, Complementary | 1 | 1999 | 461 | 0.010 |
Why?
|
Rabbits | 1 | 1999 | 710 | 0.010 |
Why?
|
Lupus Erythematosus, Systemic | 1 | 1999 | 192 | 0.010 |
Why?
|
Base Sequence | 1 | 1999 | 3090 | 0.010 |
Why?
|
Signal Transduction | 1 | 2007 | 4496 | 0.010 |
Why?
|
Molecular Sequence Data | 1 | 1999 | 3877 | 0.010 |
Why?
|
Antibodies, Monoclonal | 1 | 1999 | 1031 | 0.010 |
Why?
|